Tota published a blog post explaining the different types of testing methods available, including third-generation metagenomic sequencing.
Public source
Publisher name
Public post
I've spent a lot of this year working on how to explain our science in plain English (it's always a work in progress! 😆) so here's my best go at the bit that really mat…
Company
Tota
Know your body, totally.
- Industry
- Biotechnology Research
- Company size
- 2–10 employees
About Tota
Our mission is to give people the information they deserve about their bodies. Tota is a home-to-lab vaginal and urinary microbiome test, powered by 3rd generation metagenomic sequencing - because women deserve better. Women's health has made progress. Period tracking, fertility apps, gut health - all crowded, all growing. But the vaginal and urinary microbiome, despite affecting millions of women every year, remains one of the most under-researched and underserved areas in health. That's the gap we're building for. The problem isn't a lack of care. It's a lack of information. Traditional testing looks for a predefined list of organisms, not everything that's actually there. You can't solve a problem you can't see. Tota's test reads everything present in the vaginal and urinary microbiome, not a pre-written list of usual suspects. We're filling the information gap that's left too many women without answers for too long. This is only the beginning. Our vision is a new standard for how people understand their own bodies - starting with the microbiomes no one else is looking at properly.
See moreLatest activity
Latest activity from Tota
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Cavidi
Cavidi published an in-depth explainer explaining how BOLD technology makes immunoassays 10–100x more sensitive.
Research & Knowledge
Oxford Nanopore Technologies
Oxford Nanopore Technologies published a case study on researchers using Oxford Nanopore sequencing to uncover hidden cancer signals for earlier detection and monitoring.
Research & Knowledge
Until
Until published a blog post detailing how the company built its cryoprotectant discovery engine that scaled the search from a few dozen candidate molecules to over 250,000, producing hits.
Research & Knowledge
VH Bio
VH Bio published a blog by James Briggs titled a laboratory decision guide to faster workflows for symptomatic patients and partners of known SMA carriers.
Research & Knowledge
Sequentia Biotech